Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Liabilities and Shareholders Equity (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Liabilities and Shareholders Equity for 12 consecutive years, with $125.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity rose 27.06% year-over-year to $125.1 million, compared with a TTM value of $540.9 million through Sep 2025, up 53.9%, and an annual FY2024 reading of $150.7 million, up 618.01% over the prior year.
  • Liabilities and Shareholders Equity was $125.1 million for Q3 2025 at Avalo Therapeutics, down from $126.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $150.7 million in Q4 2024 and bottomed at $21.0 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $76.3 million, with a median of $64.1 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity tumbled 61.67% in 2022, then soared 618.01% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $80.2 million in 2021, then crashed by 58.4% to $33.4 million in 2022, then tumbled by 37.08% to $21.0 million in 2023, then skyrocketed by 618.01% to $150.7 million in 2024, then decreased by 17.01% to $125.1 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for AVTX at $125.1 million in Q3 2025, $126.6 million in Q2 2025, and $138.5 million in Q1 2025.